Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma

Osei‐Bordom, Daniel; Sachdeva, Gagandeep; Christou, Niki

doi:10.3389/fmed.2021.788869

Cited by 4 publications

(4 citation statements)

References 125 publications

(129 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cell uptake studies demonstrate the potential benefits of using the developed CDs-Gd for ex vivo monitoring of cancer-associated circulating cells through fluorescence imaging. At least in principle, fluorescence imaging can be used to track cells that have internalized CDs-Gd and escaped from the primary tumor by means of liquid biopsy . Moreover, the divergent time-dependent behavior of CDs-Gd following cellular internalization in healthy and cancer cells would reflect distinct cytotoxic effects upon NIR irradiation.…”

Section: Results and Discussionmentioning

confidence: 99%

“…At least in principle, fluorescence imaging can be used to track cells that have internalized CDs-Gd and escaped from the primary tumor by means of liquid biopsy. 51 Moreover, the divergent time-dependent behavior of CDs-Gd following cellular internalization in healthy and cancer cells would reflect distinct cytotoxic effects upon NIR irradiation. This could potentially be helpful in selectively targeting and killing cancer cells while sparing healthy cells.…”

Section: Results and Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Gadolinium-Doped Carbon Nanodots as Potential Anticancer Tools for Multimodal Image-Guided Photothermal Therapy and Tumor Monitoring

Mauro,

Cillari,

Gagliardo

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

This study focuses on the synthesis and characterization of gadolinium-doped carbon nanodots (CDs-Gd) and their potential applications in multimodal imaging and precision cancer therapy. CDs-Gd were synthesized through a solvothermal decomposition method combining citric acid, GdCl 3 , and urea. The incorporation of Gd 3+ ions within the carbonaceous structure resulted in stable CDs-Gd with a peculiar architecture that retained optical and paramagnetic properties. Combined characterization techniques confirmed the presence of pH-sensitive COOH functions on the CDs-Gd surface along with the unique lattice structure induced by Gd 3+ doping. The optical properties of CDs-Gd exhibited a tunable emission spectrum displaying blue-green emission with pH-dependent behavior. Additionally, CDs-Gd exhibited contrast-enhancing properties in T 1 -weighted magnetic resonance imaging (MRI) experiments. MRI acquisitions at different Gd 3+ concentrations and pH values demonstrated the potential of CDs-Gd as contrast agents for monitoring pH changes in an aqueous environment. We found that the relaxivity of CDs-Gd at pH 5.5 (tumor, 11.3 mM −1 s −1 ) is roughly 3-fold higher than that observed at pH 7.4 (physiological, 5.0 mM −1 s −1 ) and outperformed clinical standards such as γ-butyrol (3.3 mM −1 s −1 ). Monitoring pH changes in tumor microenvironment (TME) is crucial for evaluating the effectiveness of anticancer treatments and understanding tumor progression. Furthermore, CDs-Gd demonstrated concentration-dependent photothermal conversion ability in the near-infrared (NIR) region, allowing for efficient heat generation under laser irradiation. This indicates the potential application of CDs-Gd in image-guided photothermal therapy (IG-PTT) for cancer treatment. The in vitro studies on MCF-7 (breast cancer) and 16-HBE (healthy bronchial epithelium) cell lines demonstrated that CDs-Gd exhibited high biocompatibility (cell viability >80%). However, upon NIR activation, they showed potent anticancer effects by inhibiting tumor cell proliferation and inducing apoptosis selectively in cancer cells. In conclusion, the synthesized CDs-Gd nanoparticles possess unique optical, photothermal, and MRI contrast properties, making them promising candidates for multimodal imaging-guided precision cancer therapy applications.

show abstract

Section: Results and Discussionmentioning

confidence: 99%

Section: Results and Discussionmentioning

confidence: 99%

Gadolinium-Doped Carbon Nanodots as Potential Anticancer Tools for Multimodal Image-Guided Photothermal Therapy and Tumor Monitoring

Mauro,

Cillari,

Gagliardo

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…The monitoring of treatment response is also important to avoid ineffective therapies and unnecessary side effects. Moreover, many studies have analyzed the ctDNA value as a prognostic marker for clinical outcomes and as a tool for monitoring treatment response [289][290][291].…”

Section: Treatment Response Monitoring and Prognostic Valuementioning

confidence: 99%

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer

Caputo

Ciardiello

Corte

et al. 2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decision-making. It analyzes different blood-circulating biomarkers and circulating tumor DNA (ctDNA) is the preferred one. Nevertheless, tissue biopsy remains the gold standard for molecular evaluation of solid tumors whereas liquid biopsy is a complementary tool in many different clinical settings, such as treatment selection, monitoring treatment response, cancer clonal evolution, prognostic evaluation, as well as the detection of early disease and minimal residual disease (MRD). A wide number of technologies have been developed with the aim of increasing their sensitivity and specificity with acceptable costs. Moreover, several preclinical and clinical studies have been conducted to better understand liquid biopsy clinical utility. Anyway, several issues are still a limitation of its use such as false positive and negative results, results interpretation, and standardization of the panel tests. Although there has been rapid development of the research in these fields and recent advances in the clinical setting, many clinical trials and studies are still needed to make liquid biopsy an instrument of clinical routine. This review provides an overview of the current and future clinical applications and opening questions of liquid biopsy in different oncological settings, with particular attention to ctDNA liquid biopsy.

show abstract

“…The most probable reason behind the rareness of CTCs in circulation is their size. They are often three to five times bigger than the size of the capillary openings prior to the entrance into central circulation through the portal vein [ 100 ]. Henceforth, the number of CTCs may vary both spatially and temporally, raising the questions of whether the sampling location should be redirected in hope of an early diagnosis and whether CTCs are the real source of systemic metastasis [ 101 , 102 , 103 ].…”

Section: Circulating Tumour Cells (Ctcs)mentioning

confidence: 99%

A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma

Stosic,

Senar,

Tarfouss

et al. 2023

Cells

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma is one of the most lethal malignant diseases, with a mortality rate being close to incidence. Due to its heterogeneity and plasticity, as well as the lack of distinct symptoms in the early phases, it is very often diagnosed at an advanced stage, resulting in poor prognosis. Traditional tissue biopsies remain the gold standard for making a diagnosis, but have an obvious disadvantage in their inapplicability for frequent sampling. Blood-based biopsies represent a non-invasive method which potentially offers easy and repeated sampling, leading to the early detection and real-time monitoring of the disease and hopefully an accurate prognosis. Given the urgent need for a reliable biomarker that can estimate a patient’s condition and response to an assigned treatment, blood-based biopsies are emerging as a potential new tool for improving patients’ survival and surveillance. In this article, we discuss the current advances and challenges in using liquid biopsies for pancreatic cancer, focusing on circulating tumour DNA (ctDNA), extracellular vesicles (EVs), and circulating tumour cells (CTCs), and compare the performance and reliability of different biomarkers and combinations of biomarkers.

show abstract

Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma

Abstract: Pancreatic ductal adenocarcinomas (PDAC) represent one of the deadliest cancers worldwide. Survival is still low due to diagnosis at an advanced stage and resistance to treatment. Herein, we review the main types of liquid biopsy able to help in both prognosis and adaptation of treatments.

Cited by 4 publications

References 125 publications

Gadolinium-Doped Carbon Nanodots as Potential Anticancer Tools for Multimodal Image-Guided Photothermal Therapy and Tumor Monitoring

Gadolinium-Doped Carbon Nanodots as Potential Anticancer Tools for Multimodal Image-Guided Photothermal Therapy and Tumor Monitoring

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer

A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma

Contact Info

Product

Resources

About